Skip to Main Content

Paper Details

Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial.
Clin Infect Dis
88
2022
Author NameAffiliation
Fernanda P SilveiraUniversity of Pittsburgh and University of Pittsburgh Medical Center
  • 1 - 1

Datasets

Release 1.2